<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37553659</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1752-1947</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>09</Day></PubDate></JournalIssue><Title>Journal of medical case reports</Title><ISOAbbreviation>J Med Case Rep</ISOAbbreviation></Journal><ArticleTitle>Lupus mastitis and antiphospholipid syndrome treated with anticoagulation and immunosuppression: a case report.</ArticleTitle><Pagination><StartPage>356</StartPage><MedlinePgn>356</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">356</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13256-023-04054-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Systemic lupus erythematosus is an autoimmune disease that can have cutaneous and systemic manifestations. Lupus panniculitis, also known as lupus mastitis, is a subset of chronic cutaneous lupus erythematosus that involves inflammation of the subcutaneous fat. The pathogenesis of lupus mastitis is not fully understood. Diagnosis involves a combination of skin manifestations, imaging, and pathologic confirmation. Treatment typically includes steroids and antimalarials, with more severe disease requiring additional immunosuppressive medications. This report highlights a case of lupus mastitis treated with rituximab and a possible relationship between this disease process and thrombotic disease.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 48-year-old African American female with systemic lupus erythematosus and antiphospholipid syndrome presented with new breast lesion. Mammography revealed calcifications and increased density with coarse trabecular pattern. Breast biopsy showed features of cutaneous lupus and occlusive vasculopathy. The patient was diagnosed with lupus mastitis and treated with anticoagulation, rituximab, mycophenolate mofetil, and quinacrine with resolution of her symptoms.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This patient experienced improvement in her breast symptoms with combination therapy including rituximab. There are only two other cases reported in literature of patients with lupus mastitis responding to rituximab, highlighting the possible role of B cell depleting therapy for those who have contraindications to standard treatments for lupus mastitis. While the pathophysiology of lupus mastitis is thought to be immune driven, some literature suggests that associated thrombosis commonly seen may be due to a physiologic overlap similar to antiphospholipid syndrome. The possible relationship between antiphospholipid syndrome and lupus mastitis and the use of antiplatelet and anticoagulation therapy is discussed and may warrant further investigation.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Lauren J</ForeName><Initials>LJ</Initials><Identifier Source="ORCID">0000-0003-1834-8825</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Chicago Medical Center, 1000 E. 53rd St, Apt 412S, Chicago, IL, 60615, USA. lphill@umich.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quimson</LastName><ForeName>Laarni C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Section of Rheumatology, University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onajin</LastName><ForeName>Oluwakemi</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Section of Dermatology, University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trotter</LastName><ForeName>Kimberly C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Section of Rheumatology, University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Case Rep</MedlineTA><NlmUniqueID>101293382</NlmUniqueID><ISSNLinking>1752-1947</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008413" MajorTopicYN="Y">Mastitis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">Breast lesion</Keyword><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">Lupus erythematosus panniculitis</Keyword><Keyword MajorTopicYN="N">Lupus mastitis</Keyword></KeywordList><CoiStatement>No authors have competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>9</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>8</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37553659</ArticleId><ArticleId IdType="pmc">PMC10410827</ArticleId><ArticleId IdType="doi">10.1186/s13256-023-04054-1</ArticleId><ArticleId IdType="pii">10.1186/s13256-023-04054-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Voizard B, Lalonde L, Sanchez LM, et al. Lupus mastitis as a first manifestation of systemic disease: about two cases with a review of the literature. Eur J Radiol. 2017;92:124&#x2013;131. doi: 10.1016/j.ejrad.2017.04.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejrad.2017.04.023</ArticleId><ArticleId IdType="pubmed">28624010</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulabchand R, Hafidi A, Van De Perre P, et al. Mastitis in autoimmune diseases: review of the literature, diagnostic pathway, and pathophysiological key players. J Clin Med. 2020;9(4):958. doi: 10.3390/jcm9040958.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9040958</ArticleId><ArticleId IdType="pmc">PMC7231219</ArticleId><ArticleId IdType="pubmed">32235676</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa M, Mohammadi A. Lupus mastitis: a review. Ann Diagn Pathol. 2013;17(2):230&#x2013;233. doi: 10.1016/j.anndiagpath.2012.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anndiagpath.2012.09.003</ArticleId><ArticleId IdType="pubmed">23190681</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraga K, Garcia-Diez A. Lupus erythematosus panniculitis. Dermatol Clin. 2008;26(4):453&#x2013;463. doi: 10.1016/j.det.2008.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.det.2008.06.002</ArticleId><ArticleId IdType="pubmed">18793977</ArticleId></ArticleIdList></Reference><Reference><Citation>Ts H, Lj J, Ma M, et al. Low dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol Res. 2003;139:50&#x2013;54. doi: 10.1001/archderm.139.1.50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archderm.139.1.50</ArticleId><ArticleId IdType="pubmed">12533164</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcardle A, Baker JF. A case of refractory lupus erythematosus profundus responsive to rituximab [case report] Clin Rheumatol. 2009;28:745&#x2013;746. doi: 10.1007/s10067-009-1158-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-009-1158-3</ArticleId><ArticleId IdType="pubmed">19343472</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieu V, O&#x2019;Brien T, Yap LM, et al. Refractory subacute cutaneous lupus erythematous successfully treated with rituximab. Aust J Dermatol. 2009;50(3):202&#x2013;206. doi: 10.1111/j.1440-0960.2009.00539.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-0960.2009.00539.x</ArticleId><ArticleId IdType="pubmed">19659984</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt R, Robinson M, Patel R, Franks A. Antiphospholipid-antibody-associated panniculitis. Dermatol Online J. 2012;18(12):18. doi: 10.5070/D30W81Q5ZS.</Citation><ArticleIdList><ArticleId IdType="doi">10.5070/D30W81Q5ZS</ArticleId><ArticleId IdType="pubmed">23286808</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai S, Katsuoka K, Eto H. An unusual form of lupus erythematosus profoundus associated with antiphospholipid syndrome: report of two cases. Acta Derm Venereol. 2013;93:581&#x2013;582. doi: 10.2340/00015555-1528.</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/00015555-1528</ArticleId><ArticleId IdType="pubmed">23303396</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Mazuecos J, Yebra-Bango M, Sanchez-Ruiz A, Villarreal-Garcia-Lomas M. Weber-Christian disease associated with lupus anticoagulant and anticardiolipin antibodies. Rheumatology (Oxford) 1999;38:796. doi: 10.1093/rheumatology/38.8.796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/38.8.796</ArticleId><ArticleId IdType="pubmed">10501442</ArticleId></ArticleIdList></Reference><Reference><Citation>Renfro L, Franks AG, Grodberg M, et al. Painful nodules in a young female. Arch Dermatol. 1992;128:847. doi: 10.1001/archderm.1992.01680160133022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archderm.1992.01680160133022</ArticleId><ArticleId IdType="pubmed">1599278</ArticleId></ArticleIdList></Reference><Reference><Citation>Nousari HC, Kimyai-Asadi A, Santana H, et al. Generalized lupus panniculitis and antiphospholipid syndrome in a patient without complement deficiency. Pediatr Dermatol. 1999;16(4):273&#x2013;276. doi: 10.1046/j.1525-1470.1999.00060.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1470.1999.00060.x</ArticleId><ArticleId IdType="pubmed">10469410</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris RB, Winkelmann RK. Lupus mastitis. Arch Dermatol. 1978;114(3):401&#x2013;402. doi: 10.1001/archderm.1978.01640150046014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archderm.1978.01640150046014</ArticleId><ArticleId IdType="pubmed">564666</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>